

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

Form 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of February 2021
Commission File Number 001-38370

CollPlant Biotechnologies Ltd.
(Exact name of registrant as specified in its charter)

**4 Oppenheimer St, Weizmann Science Park
Rehovot 7670104, Israel**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐

This Report on Form 6-K (excluding Exhibit 99.1 and Exhibit 99.2) is hereby incorporated by reference into the registrant's Registration Statements on Form S-8 (File No. 333-229163 and 333-248479) and Form F-3 (File No. 333-229486, 333-228054 and 333-238731), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On February 5, 2021, CollPlant Ltd. ("CollPlant"), a wholly-owned subsidiary of CollPlant Biotechnologies Ltd. (the "Company"), entered into a Development, Exclusivity and Option Products Agreement (the "Agreement") with certain wholly-owned subsidiaries of AbbVie Inc. (collectively, "AbbVie"), pursuant to which CollPlant and AbbVie will collaborate in the development and commercialization of dermal and soft tissue filler products for the medical aesthetics market, using CollPlant's recombinant human collagen (rhCollagen) technology.

Pursuant to the Agreement, CollPlant agreed to undertake projects for the development of an aseptic process for sterile rhCollagen that meets or exceeds certain specifications as set forth in the Agreement. Prior to the second anniversary of the Agreement, AbbVie may elect to have CollPlant undertake additional projects for the development of a more concentrated rhCollagen that meets or exceeds certain specifications.

Pursuant to the Agreement, CollPlant granted to AbbVie and its affiliates, worldwide exclusive rights to use its rhCollagen in combination with AbbVie proprietary technologies, for the production and commercialization of dermal and soft tissue filler products (the "Exclusive Products"). Further, pursuant to the Agreement, CollPlant granted to AbbVie and its affiliates, a right of first negotiation to enter into a definitive agreement to obtain exclusive, worldwide rights to the use of CollPlant rhCollagen for the commercialization and sale of an injectable breast implant product and a right of first negotiation to enter into a definitive agreement to obtain exclusive, worldwide rights to the use of CollPlant rhCollagen for the commercialization and sale of a photocurable dermal filler product (each an "Option Product" and together, the "Option Products"). Other than under the Agreement, CollPlant has agreed not to research, develop or commercialize its rhCollagen for use with any Exclusive Products during the term of the Agreement or grant any third party any rights to CollPlant's rhCollagen technology that would conflict with rights granted to AbbVie.

The Agreement provides that later on CollPlant and AbbVie will enter into a supply agreement whereby CollPlant will manufacture and supply AbbVie with rhCollagen, at a pre-agreed price, to be used solely for the development and manufacture of the Exclusive Products and Option Products.

The Agreement provides that with respect to the Exclusive Products CollPlant shall be entitled to receive up to \$50 million comprised of an upfront cash payment of \$14 million and up to \$36 million in proceeds upon the achievement of certain development, clinical trial, regulatory and commercial sale milestones. In addition, CollPlant shall be entitled to a fixed-fee royalty payment (subject to certain adjustments) for each product commercially sold during the applicable royalty term as well as a fee for the supply of rhCollagen to AbbVie. In addition, with respect to the Option Products, CollPlant shall be entitled to receive up to \$53 million, as further described below, plus a fixed-fee royalty payment (subject to certain adjustments) for each product commercially sold during the applicable royalty term and a fee for the supply of rhCollagen to AbbVie. The \$53 million in proceeds includes a one-time non-refundable payment of \$6 million upon signing a definitive agreement with regard to the injectable breast implant product; a one-time non-refundable payment of \$4 million for signing a definitive agreement with regard to the photocurable dermal filler product; and up to an additional \$43 million payable upon the achievement of certain clinical trial, regulatory approval and commercial sale milestones.

Unless earlier terminated, the Agreement will continue in effect on a product-by-product and country-by-country basis until the later of (i) the expiration, invalidation or abandonment of the last CollPlant patent covering a product in a particular country, and (ii) 10 years from the first commercial sale of such product in such country. Following expiration (unless earlier terminated), the rights granted to AbbVie in the Agreement will continue on a non-exclusive, fully paid-up, royalty-free, perpetual and irrevocable basis. The Agreement may be terminated early by either party for material breach or bankruptcy. In addition, AbbVie may terminate the Agreement at any time immediately upon written notice to CollPlant if AbbVie reasonably believes that it is not advisable for AbbVie to continue to develop or commercialize the Exclusive Products under the Agreement as a result of a perceived serious safety issue regarding the use of any Exclusive Product or upon 60 days' written notice, for any or no reason, with respect to its rights under the Agreement on an Exclusive Product-by-Exclusive Product or country-by-country basis.

On February 8, 2021, the Company issued a press release announcing entry into of the Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In addition, the Company has posted to its website an updated corporate presentation. A copy of the presentation is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

99.1 [Press Release, dated February 8, 2021](#)

99.2 [Corporate Presentation, dated February 8, 2021](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

COLLPLANT BIOTECHNOLOGIES LTD.

Date: February 8, 2021

By: /s/ Eran Rotem

Name: Eran Rotem

Title: Deputy CEO and Chief Financial Officer



CollPlant Announces Development and Global Commercialization Agreement with Allergan Aesthetics, an AbbVie company, for rhCollagen in Dermal and Soft Tissue Filler Products

Potential to receive up to \$103 million in upfront and milestone payments, in addition to royalties and other payments

REHOVOT, Israel, February 8, 2021 /PRNewswire/ — CollPlant Biotechnologies (NASDAQ:CLGN) today announced it has entered into a worldwide exclusive development and commercialization agreement for dermal and soft tissue filler products with Allergan Aesthetics, an AbbVie company.

CollPlant has granted Allergan Aesthetics worldwide exclusivity to use its plant-derived recombinant human collagen (rhCollagen) in combination with Allergan Aesthetics' proprietary technologies, for the production and commercialization of dermal and soft tissue fillers. In addition, Allergan Aesthetics has the right of first negotiation for CollPlant's technology in two future additional products.

CollPlant will receive an upfront payment of \$14 million and is entitled to receive up to an additional \$89 million in milestone payments. In addition, CollPlant is eligible to receive royalty payments and a fee for the manufacture and supply of rhCollagen to Allergan Aesthetics.

Yehiel Tal, Chief Executive Officer of CollPlant, stated, "We are very pleased to formalize this collaboration with Allergan Aesthetics, the worldwide leader in dermal and soft tissue fillers. We believe that combining technologies from Allergan Aesthetics and CollPlant will create a paradigm shift in the medical aesthetics field. CollPlant's rhCollagen is non-immunogenic and non-allergenic, and offers better tissue regeneration performance over animal-derived collagen which is currently used in medical aesthetics. This agreement further validates CollPlant's technology as the gold standard collagen for regenerative and aesthetic medicine. We look forward to a highly productive partnership."

Roger J. Pomerantz, MD, FACP, Chairman of the Board of Directors at CollPlant, said, "Our company is extremely excited to expand our work in medical aesthetics towards commercialization in the dermal filler market, which is projected to reach \$10 billion by 2026. This collaboration is a major step forward, firmly placing CollPlant at the next level in applying our regenerative medicine technology to tackle new areas in biomedicine."

About CollPlant

CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. CollPlant's products are based on its rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology.

CollPlant's products address indications for the diverse fields of tissue repair, aesthetics and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.

CollPlant's flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. In 2018, CollPlant entered into a licensing agreement with United Therapeutics, whereby United Therapeutics is using CollPlant's BioInks in the manufacture of 3D bioprinted lungs for transplant in humans.

For more information, visit <http://www.collplant.com>.

Contacts at CollPlant:

Eran Rotem
Deputy CEO & Chief Financial Officer
Tel: + 972-73-2325600/631
Email: Eran@collplant.com

Safe Harbor for Forward-Looking Statements

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: CollPlant's history of significant losses and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; CollPlant's expectations regarding the timing and cost of commencing clinical trials with respect to products which are based on CollPlant's rhCollagen; CollPlant's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to the products, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the products; CollPlant's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third-party distributors and resellers; CollPlant's ability to establish and maintain strategic partnerships and other corporate collaborations; CollPlant's reliance on third parties to conduct some aspects of its product manufacturing; the scope of protection CollPlant is able to establish and maintain for intellectual property rights and the companies' ability to operate their business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the companies operate; projected capital expenditures and liquidity; changes in the companies' strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant is contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F, respectively, filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and neither company undertakes, and each company specifically disclaims, any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CollPlant Overview



CollPlant
Biotechnologies

Pioneering
Regenerative
Medicine

February 2021

Safe Harbor Statement

Certain statements in this presentation constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Risks and uncertainties for our company include, but are not limited to: the Company's history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based BioInk, dermal fillers for aesthetics, breast implants, VergenixSTR, and VergenixFG; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk, dermal fillers for aesthetics, breast implants, VergenixSTR, and VergenixFG including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based BioInk, dermal fillers for aesthetics, breast implants, VergenixSTR, and VergenixFG; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected

capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. Many of these factors that will determine actual results are beyond our ability to control or predict. For a discussion of the factors that may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied in such forward-looking statements, see the "Risk Factors" section of included in our most recently filed Annual Report on Form 20-F. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

The statements made in this presentation speak only as of the date stated herein, and subsequent events and developments may cause our expectations and beliefs to change. Unless otherwise required by applicable securities laws, we do not intend, nor do we undertake any obligation, to update or revise any forward-looking statements contained in this presentation to reflect subsequent information, events, results or circumstances or otherwise. While we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law.


The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.

CollPlant overview


- A regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing
- Proprietary technology platform that enables mass production of recombinant human collagen (rhCollagen)
- rhCollagen-based products aimed at 3D Bioprinting of tissues and organs, and medical aesthetics markets
- Strategic agreements with:
 - AbbVie (NASDAQ: ABBV) - for worldwide exclusive development and commercialization of dermal and soft tissue fillers
 - United Therapeutics (NASDAQ: UTHR) - for 3D bioprinting of lung, kidney transplants and other life saving organs
- Active business development strategy with multiple opportunities in various stages of development



Experienced management team



Prof. Oded Shoseyov
Co-Founder & Chief Scientist
Pauli Clean Tech
CBD Tech.
Fulcrum-SPD
Melodea
Hebrew University




Yehiel Tal
CEO
Regentis Biomaterials
ProChon Biotech
Kulicke & Soffa Industries




Eran Rotem
Deputy CEO & CFO
Tefron, CFO (NYSE, TASE)
Healthcare Tech., CFO
(NASDAQ) & Gamida
E&Y



Nadav Orr, PhD
VP R&D
Ethicon Biosurgery,
Johnson & Johnson



Ilana Belzer, PhD
COO
BioHarvest
Procognia Ltd.
Omrix Biopharmaceuticals
Interpharm



Philippe Bensimon, PharmD
VP RA/QA/CA
Maquet Getinge
3M Medical

Board of directors



Dr. Avri Havron
Board member

Kamada
PROLOR Biotech (acquired by Opko Health)
Clal Biotechnology Industries
BioTechnology General
Interpharm Laboratories



Dr. Roger Pomerantz
Chairman

ContraFect
VerlImmune
Seres Therapeutics
Merck
J&J



Dr. Gili Hart
Board member

Ayala Pharmaceuticals
SpliSense
Mitoconix
OPKO Biologics
PROLOR Biotech (acquired by Opko Health)



Dr. Elan Penn
Board member

A.I. Research and Development
Sivan Computer Training Company
Mashov Computers
Magic Software Enterprises
Telkoor Power Supplies
Nexgen Biofuels



Joseph Zarzewsky
Board member

Mitrelli Group
SMAD

Advisory Board

Prof. Avram Hershko

Unit Of Biochemistry, Technion
Nobel Laureate in Chemistry 2004

Dr. Joseph M. Lane

Orthopaedic Surgeon at Hospital
for Special Surgery, New York

Prof. Vicki Rosen

Department of Developmental Biology,
Harvard University School of Dental Medicine

Prof. Ofer Levy

Shoulder and Elbow Surgeon
Director of the Reading Shoulder Unit, UK

Prof. Shay Soker

Professor of Regenerative Medicine and the Scientific
Officer for Wake Forest Institute for Regenerative Medicine



Prof. Abhay Pandit

Director of Strategic Research Cluster "Network of
Excellence for Functional Biomaterials" (NFB) at the
National University of Ireland, Galway




Transgenic tobacco plants

Expressing 5 human genes



Large scale human collagen produced in tobacco plants



rhCollagen- The ideal building block for tissue and organ transplants used in regenerative medicine

Clear advantages over tissue-extracted collagen



Better bio-functionality

- Accelerates human cell proliferation
- Faster tissue healing



Superior homogeneity


- Controlled physical/rheological properties
- Reproducibility
- Transparency (not visible)




Improved safety and greater purity

- Non-immunogenic
- Non-allergenic
- No pathogens
- No foreign body response

Plant-derived



Tissue Extracted



Product Pipeline

Aesthetic medicine

Dermal/soft tissue fillers



Collaboration with

an AbbVie company



Photocurable
dermal filler*



Injectable breast
implants*

3D bioprinting

3D bioprinted products




Breast implants



Lung and Kidney-
collaboration with



Biolnk formulations



Soft and hard
tissues

3D Bioprinted Tissues and Organs



A great medical need for supply of life saving organs



~30,000

US transplants per year



115,000

US waiting list




900,000

US deaths per year from organ impairment

3D bioprinting expected to bridge this gap and allow unlimited supply of life saving organs

The technological building blocks already exist – a system integrator is needed to assemble them all together



3D Bioprinting Major Segments Representing a Multi- Billion Dollar Market Opportunity

Organs



- Lungs
- Kidney
- Liver
- Heart

Endocrine glands



- Ovary
- Pancreas
- Thyroid

Tissues



- Breast
- Skin
- Cornea
- Bones
- Cartilage
- Heart valve

Scaffolds



- Spine fusion
- Non-union fractures
- Craniomaxillofacial
- Nerve conduits
- Tendons, ligaments
- Bones

Drug discovery




- Mimic pathologic tissue (efficacy)
- Mimic healthy tissue (safety)
- High throughput

rhCollagen BioInk

Compositions in development (with partners/collaborators)



Collaboration agreement with United Therapeutics (2018)



- Global licensing and commercialization agreement for 3D Bioprinting of solid organ scaffolds for human transplants
- Collaboration combines CollPlant's proprietary BioInk technology and United Therapeutics' regenerative medicine and organ manufacturing capabilities


Agreement highlights:

- \$5M upfront payment
- Up to \$39M milestone and option payments
- Royalties on product sales
- United Therapeutics has the option to expand the license to add up to three organs*
- United Therapeutics will establish a U.S. facility for the manufacture of CollPlant's rhCollagen and BioInk


14

* In September 2020, United Therapeutics expanded the collaboration with the exercise of its option to cover a second lifesaving organ, human kidneys. United Therapeutics paid CollPlant \$3 million for the option exercise

3D bioprinting examples



*3D bioprinting of trachea using CollPlant's BioInk.
Courtesy of United Therapeutics*



Bioprinting of soft tissue implant

3D Systems and CollPlant Biotechnologies Join Forces to Accelerate Breakthroughs in Regenerative Medicine English ▾

NEWS PROVIDED BY
CollPlant →
Jan 13, 2020, 08:00 ET

SHARE THIS ARTICLE
[f](#) [t](#) [in](#) [p](#) [v](#)

ROCK HILL, South Carolina and REHOVOT, Israel, Jan. 13, 2020 /PRNewswire/ -- Today, 3D Systems (NYSE: DDD) and CollPlant Biotechnologies (NASDAQ: CLGN), announced signing a joint development agreement intended to play a pivotal role in advancing and accelerating breakthroughs in the biomedical industry. The collaboration brings together two industry pioneers--3D Systems, renowned for its 3D printing technologies and healthcare expertise; and CollPlant, the developer of proprietary recombinant human collagen (rhCollagen) Biolnk technology currently used for 3D bioprinting of tissues and organs. The two companies plan to jointly develop tissue and scaffold bioprinting processes for third party collaborators.

- 3D bioprinted soft tissue implant with vascularization channels perfused with red ink
- The implant was printed using 3D Systems' high resolution bioprinter and Biolnk that is based on CollPlant's rhCollagen

16



Breast implants



Breast implants market overview

Current breast reconstruction is based on synthetic breast implantation, free flap surgery/autologous fat tissue transfer - all of which replace tissue rather than regenerate it.



\$1.4B Market

worldwide (2018)¹



\$ 5-10K Cost

per full procedure in US²




~2,500,000

Breast implant procedures WW (2019)³

~550,000 in US (2019)⁴

Procedure (US segmentation)



■ Breast augmentation

■ Breast lift

■ Breast reconstruction




FDA alert: Patients with breast implants have an increased risk of developing breast implant Associated- Anaplastic Large Cell Lymphoma (Feb 2019)⁵

1. Analytical Research Cognizance, Global Breast Implant Market, March 2019
2. <https://www.webmd.com/beauty/cosmetic-procedures-breast-augmentation#1>
3. <https://www.isaps.org/wp-content/uploads/2020/12/Global-Survey-2019.pdf>
4. <https://www.plasticsurgery.org/documents/News/Statistics/2019/plastic-surgery-statistics-full-report-2019.pdf>
5. <https://www.fda.gov/medical-devices/letters-health-care-providers/breast-implant-associated-anaplastic-large-cell-lymphoma-bia-acll-letter-health-care-providers>


CollPlant's 3D biprinted breast implants




Breast scaffold bioprinting



ECM components +
autologous fat cells loading



Implantation and
vascularization



Implant replacement by
newly formed tissue

Dermal/Soft tissue fillers



Dermal fillers market overview



~2,160,578

HA procedures in 2019 in the US¹



>\$6.2B, 7.6% CAGR


Global dermal filler market, 2019²
CAGR 2020-2026²



\$100-\$250/unit

Cost per syringe³

2019 Procedure breakdown, U.S
(by material)¹



Collaboration agreement with AbbVie (Feb. 2021)




- A worldwide exclusive development and commercialization agreement for dermal and soft tissue fillers for the medical aesthetics market
- Combines CollPlant's proprietary rhCollagen technology and AbbVie's technology
- Expands CollPlant's regenerative medicine programs and further validates our technology

Agreement highlights:

- Up to \$103M in potential payments, including:
 - \$14M upfront payment
 - Up to \$89 milestones and option payments
- Royalties on products sales
- AbbVie has the right of first negotiation for CollPlant's technology in two additional products, an injectable breast implant and a photocurable dermal filler
- CollPlant will manufacture and sell to AbbVie the rhCollagen used in the products

rhCollagen-based Photocurable regenerative dermal filler key attributes



Injectable breast implants*

- Composed of rhCollagen, additional materials and fat cells taken from the patient
- Intended to promote breast tissue regeneration
- Designed to support the viability and function of the autologous fat cells, and to attract cells to promote tissue regeneration
- **The scaffold is designed to gradually degrade and be replaced by newly grown natural breast tissue that is free of any foreign material**



51 employees



Strong R&D team



Fully integrated



Production team
with proven **track
record**

NASDAQ (CLGN),

NASDAQ listed since Jan 2018



Revenue (ttm*):
\$6.02M



Market Cap:
\$118M**



Ave vol (3m):
41k shares

*ttm – trailing twelve months

** As of Feb 5, 2021



CollPlant investment highlights



Only commercially viable technology
currently available that can produce
truly human collagen



Strategic agreement with ABBV
Strategic agreement with UTHR



Multi-billion dollar market:
innovative rhCollagen products initially aimed
at 3D bioprinting and medical aesthetics



Clinically validated technology



Broadly applicable technology:
Ideal building block/scaffolding
molecule for regenerative medicine



Proven management team

Thank you



CollPlant
Biotechnologies

Pioneering
Regenerative
Medicine